C. Kent Osborne and Rachel Schiff Laboratory

Selected Publications

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. [PDF]

Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I.
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7. [PDF]

Osborne CK, Schiff R.
Aromatase inhibitors: future directions.
J Steroid Biochem Mol Biol. 2005 May;95(1-5):183-7. [PDF]

Osborne CK, Schiff R.
Estrogen-receptor biology: continuing progress and therapeutic implications.
J Clin Oncol. 2005 Mar 10;23(8):1616-22. Review. No abstract available. [PDF]

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M.
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
J Clin Oncol. 2005 Apr 10;23(11):2469-76. Epub 2005 Mar 7. [PDF]

Osborne CK, Shou J, Massarweh S, Schiff R.
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Review [PDF]

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. [PDF]

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK.
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S. [PDF]

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R.
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. [PDF]